4C Medical Technologies (Brooklyn Park, MN) is focused on minimally invasive therapies for structural heart disease, specifically mitral valve regurgitation.
ATRO Medical (Nijmegen, Netherlands) – TRAMMPOLIN (Total ReplAcement of Meniscus with Minimally invasive POLymer ImplaNt) is a synthetic, non‐resorbable total meniscus substitute.
Beta Bionics (Boston, MA) has developed iLet, the world’s first bionic pancreas.
Most people with diabetes on insulin therapy are unable to manage glucose levels within the recommended targets. iLet is a fully autonomous device, which provides revolutionary simplicity in diabetes management by being able to achieve near normal glycemic in most situations of life based on Beta Bionics’ machine learning algorithms, which have been successfully tested in clinical studies.
Body Vision Medical (Sharon, Israel) offers innovative LungVision platform, that transforms peripheral lung biopsy into accurate and affordable option, providing substantial clinical benefits. Our solution is powered by artificial intelligence technology to address unmet clinical need for early-stage lung cancer diagnostics and treatment.
Braster (Warsaw, Poland) developed and commercialised a mHealth system to support women in breast examination. It uses medical device, app and AI to analyse examinations and prepare result.
BriteSeed (Chicago, IL) is an advanced surgery company building smart minimally invasive tools to the operating room that provide imaging of hidden structures, including blood vessels and ureters. These tools use advanced optical hardware and a smart vision engine that has the potential to make surgery safer and faster. Leveraging machine learning and novel hardware, Briteseed will be rolling out the next generation of surgical graspers, vessel sealers, and blunt-tipped dissectors.
Carmell Therapeutics (Pittsburgh, PA) has created a unique and highly innovative patented technology based on biologically-active materials manufactured from human blood plasma. Our proprietary process binds and cross-links lyophilized plasma into solid and semi-solid plasma-based materials. These Plasma-based Bioactive Materials (PBMs) contain highly concentrated natural regenerative factors that promote healing in various clinical settings, reduce infections, and, as a result, lower healthcare costs.
Conavi Medical (Toronto, Ontario, Canada) develops image guidance technologies for use in minimally invasive procedures with an initial focus in cardiology.
CorFlow Therapeutics AG (Baar, Switzerland) is developing the first combined diagnostic and therapeutic medical device for improving microvascular obstructions after a heart attack.
CorWave (Clichy, France) is developing a Left Ventricular Assist Device (LVAD) that offers significant advantages over the currently available devices.
CybeReha (Geneva, Switzerland) – Robotic-assisted muscle electrostimulation leveraging neuronal plasticity in order to restore paraplegic/hemiplegic patients’ sensory-motor loop and improve rehabilitation outcomes.
Day Zero Diagnostics (Allston, MA) is developing a modern approach to the diagnosis of severe infections for an era of rising antibiotic resistance. We use DNA sequencing and machine learning to rapidly identify an infection and determine its antibiotic susceptibility profile in hours rather than days—saving lives and reducing costs.
Endo Tools Therapeutics (Gosselies, Belgium) develops devices for advanced GI interventions (bariatric surgery, GERD, bypass revision, full thickness resection); devices are CE marked (used in >150 patients, results for bariatrics exceed guidelines); market > USD 5 B.
Endotronix (Woodridge, IL), a medical technology company, is developing an integrated platform to provide comprehensive, reimbursable health management innovations for patients suffering from advanced heart failure. The company’s solution, the Cordella™ Heart Failure System, includes a cloud-based disease management data system and at-home hemodynamic management with a breakthrough implantable wireless pulmonary artery pressure sensor for early detection of worsening heart failure.
Femeda (Cramlington, United Kingdom) has developed Pelviva, a Pelvic Floor muscle re-trainer that provides women with a clinically effective, discrete and easy to use treatment for bladder leakage. It is a single use, disposable intra-vaginal medical device, made from soft compressible foam, containing a microprocessor which delivers an innovative, patented electrical stimulation treatment program with Reactive Pulse Technology to retrain and strengthen the Pelvic Floor muscles.
FineHeart (Pessac, France) – Founded in 2010, FineHeart is a French startup located in Pessac, in the Bordeaux metropolis, that is focused on creating innovative technologies in the cardiovascular field. Its new medical device, the Implantable Cardiac Output Management System (ICOMS), is a fully implantable, wirelessy powered pulsatile smart mini pump that optimizes cardiac output while preserving the innate contractility of the heart.
Galen Robotics (San Jose, CA) is bringing to market a new cooperative robotic platform designed for high precision microsurgery, based on 5 years of research and development out of the Johns Hopkins University Robotics Lab. The Galen robot is designed for microsurgical procedures, robotically assisting procedures for ENT, Spine and Neurosurgery through tremor cancellation, tool guidance and stabilization, recordable tool movement and safety barriers.
GraftWorx (Menlo Park, CA) – Medicine today is characterized by clinicians looking retrospectively at diagnostic imaging and laboratory data, which results in expensive, reactionary procedures. GraftWorx is turning the Internet of Things into the Internet of the Body by enabling current “dumb” cardiovascular implants to become “smart.” We then leverage our cloud platform to alert clinicians of potential disasters. Our first product (currently in pre-clinical trials) will save 40,000 amputations in the US each year.
HealthBeacon (Dublin, Ireland) is a medication adherence technology company. We develop smart tools for managing medication. The HealthBeacon is a smart sharps bin for patients who self-inject medications at home. It is digitally connected and programmed with a patient’s personal medication schedule, and uses customized reminders to help them start and stay on track with their medication.
Hemovent GmbH (Aachen, Germany) is an emerging medical device company that has developed disruptive technology: the world’s smallest and first self-contained fully portable Extra Corporeal Membrane Oxygenation (ECMO) system that supports or replaces heart and lung function in the event of cardiac and respiratory failure.
iSTAR Medical (Wavre, Belgium) is a clinical-stage, medical technology company focused on the development of novel ophthalmic implants for patients with glaucoma. Its lead product, called MINIject, is a next generation MIGS device, incorporating an implant made of STAR® material, which exhibits outstanding anti-fibrotic and anti-inflammatory properties leading to superior clinical outcomes.
Latch Medical (Dublin, Ireland) is pioneering a revolutionary Engineered Securement Device for catheters that is intuitive, easy to use, will deliver clinical superiority and is highly cost effective.
Loop Medical (Lutri, Switzerland) is developing a needle-free blood collection technology compatible with existing laboratory infrastructure. This venture is supported by Cerba Healthcare and the Bill and Melinda Gates Foundation.
MangoGen Pharma (Quebec, Canada) is developing gene-delivering cardiac stents and wound healing creams.
Medicem (Kladno, Czech Republic), the world leader in bioanalogic hydrogels, is developing two high value premium intraocular lenses that address the large cataract and presbyopia-correcting markets. WIOL-CF is a CE-marked extended-depth-of-focus (EDOF) lens that is expected to be launched in 2018/2019. The team is also developing FSLA-IOL, a femtosecond laser adjustable lens that can be altered post-implantation repeatedly in a non-invasive laser procedure. This product is targeted to unlock the large yet practically untapped elective-presbyopia market.
Mitre Medical (Morgan Hill, CA) is developing the Mitral Touch®, a less invasive and safer approach to treat mitral valve regurgitation (MR) in patients with moderate to severe MR.
Neuromod Devices (Dublin, Ireland) focuses on the design and development of non-invasive neuromodulation technologies for chronic and debilitating conditions including tinnitus.
NeuroRecovery Technologies (San Juan Capistrano, CA) is a pre-revenue medical device company based in Southern California commercializing technology developed at UCLA, and Cal Tech. With Expedited Access Pathway status granted by the FDA and backing by the Christopher & Dana Reeve Foundation the company is now poised to execute on a successful regulatory and commercial plan; providing innovative neuromodulation systems to advance the rehabilitation and recovery of individuals suffering with paralysis.
Newronika SRL (Milan, Italy) restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normal daily activities and improve quality of life.
Pentracor (Hennigsdorf, Germany) is a 1st in class medical device to prevent the destruction of viable heart muscle tissue in the vicinity of necrotic tissue after myocardial infarction.
Perimeter Medical Imaging (Toronto, Ontario, Canada) develops, patents, and commercializes advanced surgical imaging tools that allow surgeons, radiologists and pathologists to better assess microscopic tissue structures during surgical procedures.
PhotoniCare (Champaign, IL) has developed a handheld, low-cost imaging platform that uses light to see through tissue. The first product on this platform is a device that can see through the eardrum without cutting it open, addressing management of middle ear infections, one of the world’s most common diseases.
Physeon (Schaffhausen, Switzerland) – The Veinplicity™ device addresses the challenges for a successful first attempt peripheral IV cannulation, the most commonly performed medical intervention in the world. By its intended physiological mechanism of increasing the size of the targeted vein and its lumen, successful first stick venous cannulation rate can be significantly improved with Veinplicity™.
PMD Solutions (Cork, Ireland) – RespiraSense is the world’s only continuous respiratory rate monitor. Respiratory rate is the earliest and single most sensitive indicator of patient deterioration, making 6-12 hours timelier intervention possible to improve outcomes.
Polares Medical (Lausanne, Switzerland) is developing a mitral posterior leaflet replacement device to address the underlying cause of mitral regurgitation in both DMR and FMR patients. The company is expecting to be in first-in-man clinical study within 12 months.
Ponce De Leon Pharmaceuticals (Dublin, Ireland) is developing a product formulation aimed at postponing the onset of human frailty, and the extension of human healthspan, the healthy years of living. The company has partnered with The Buck Institute for Research on Aging, and currently is testing its product in animals, with impressive early results.
Promaxo (Rockville, MD) is a medical device company developing and commercializing an office-based and cost effective MRI with cellular level spatial resolution, real time biopsy and treatment tools, and automated software for tissue characterization. The Company’s current focus is on addressing the needs of the prostate cancer market.
ProVerum Medical (Dublin, Ireland) is an early-stage medical device company developing an innovative medical device technology to treat Benign Prostatic Hyperplasia (BPH).
Raydiant Oximetry (Mountain View, CA) has developed a novel fetal monitor that more accurately measures fetal distress. This technology will improve childbirth related outcomes for expecting mothers and their babies.
Robocath (Rouen, France) designs and develops innovative robotic solutions for improving endovascular procedures. These procedures are carried out to treat vascular diseases, including heart attacks, the leading cause of death worldwide.
RSP Systems A/S (Odense, Denmark) is dedicated to improving the health and quality of life of people worldwide through its unique and patented solution for non-invasive diagnostics. The first targeted application is a product line of noninvasive glucose monitors, which will provide diabetic patients with a convenient, pain free alternative to the current invasive solutions.
Sensimed AG (Lausanne, Switzerland) has developed a unique non-invasive soft contact lens-based solution, the SENSIMED Triggerfish®, with the aim of revolutionizing glaucoma management by providing an automated recording of continuous ocular dimensional change over 24 hours.
Synergy Disc Replacement (Boulder, CO) – Synergy-Disc is the first and only Total Disc Replacement implant that unifies the needs for sagittal balance and motion into an alignment correcting cervical disc. Proprietary alignment features allow it to be used in patients that do not have a normal alignment. This unique ability makes Synergy-Disc the only viable alternative to fusion in patients with pre-operative alignment problems.
TAS Medical (San Carlos, CA) – Our Trans Abdominal Strap will meet the large unmet need to close ventral hernia defects laparoscopically while providing millions of dollars in savings for healthcare.
VALFIX medical (Tel-Aviv, Israel) is developing a complete transcatheter annnuloplasty system by recreating the surgical procedure for the treatment of mitral regurgitation (MR). VALFIX technology can be applied to the vast majority of functional and degenerative MR patients worldwide.
Vascular Graft Solutions (Tel Aviv, Israel) is a revenue stage company active in the field of cardiovascular surgery. The company’s leading platform of external scaffolds, VEST and FRAME, was implanted in more than 1,000 patients and is currently the only available solution for preventing vein graft disease after coronary or peripheral bypass procedures. In addition, VGS develops several technologies to reduce post-operative complications and to improve the clinical outcome of surgical revascularization.
Vivior’s (Zurich, Switzerland) sensor technology provides objective behavioral data to support medical experts in offering personalized vision solutions to their patients.